Cyril B. Dousson
26Patents
9h-index
28Co-inventors
71Inventor score
Filing activity: Sep 16, 2005 → Nov 24, 2020
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US8507460B2 | Substituted 3′,5′-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections | Chemistry; Metallurgy | 48 | Active |
| US8362068B2 | 5,5-fused arylene or heteroarylene hepatitis C virus inhibitors | Chemistry; Metallurgy | 44 | Active |
| US9109001B2 | 3′,5′-cyclic phosphoramidate prodrugs for HCV infection | Chemistry; Metallurgy | 44 | Active |
| US8951985B2 | Compounds and pharmaceutical compositions for the treatment of viral infections | Human Necessities | 31 | Active |
| US9339541B2 | Thiophosphate nucleosides for the treatment of HCV | Emerging Cross-Sectional Technologies | 25 | Active |
| US7932240B2 | Phosphadiazine HCV polymerase inhibitors IV | Human Necessities | 22 | Active |
| US8193372B2 | Phosphothiophene and phosphothiazole HCV polymerase inhibitors | Chemistry; Metallurgy | 21 | Active |
| US9296778B2 | 3′,5′-cyclic phosphate prodrugs for HCV infection | Chemistry; Metallurgy | 18 | Active |
| US9403863B2 | Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections | Chemistry; Metallurgy | 11 | Active |
| US7534809B2 | Phospho-indoles as HIV inhibitors | Chemistry; Metallurgy | 5 | Active |
| US10030044B2 | Nucleotides for the treatment of liver cancer | Human Necessities | 4 | Active |
| US10449208B2 | Antiviral prodrugs of tenofovir | Human Necessities | 3 | Active |
| US10683321B2 | 4′-or nucleosides for the treatment of HCV | Chemistry; Metallurgy | 2 | Active |
| US10899788B2 | Cyclic phosphate substituted nucleoside compounds and methods of use thereof for the treatment of viral diseases | Chemistry; Metallurgy | 1 | Active |
| US8044091B2 | Phospho-indoles as HIV inhibitors | Chemistry; Metallurgy | 1 | Active |
| US7960428B2 | Enantiomerically pure phosphoindoles as HIV inhibitors | Human Necessities | 1 | Active |
| US10815264B2 | Nucleotides for the treatment of cancer | Human Necessities | 1 | Active |
| US10202411B2 | 3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV | Human Necessities | 1 | Active |
| US10513534B2 | 2′-chloro nucleoside analogs for HCV infection | Chemistry; Metallurgy | 0 | Active |
| US8486991B2 | Enantiomerically pure phosphoindoles as HIV inhibitors | Human Necessities | 0 | Active |
| US11730748B2 | Cyclic phosphate substituted nucleoside derivatives for the treatment of liver diseases | Chemistry; Metallurgy | 0 | Active |
| US10766917B2 | Nucleotides for the treatment of cancer | Chemistry; Metallurgy | 0 | Active |
| US10005779B2 | 1′,4′-thio nucleosides for the treatment of HCV | Chemistry; Metallurgy | 0 | Active |
| US9187496B2 | 5,5-fused arylene or heteroarylene hepatitis C virus inhibitors | Chemistry; Metallurgy | 0 | Active |
| US10238680B2 | D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.